Isoxicam- NSAIDs - Investigational drugs
Drug Name:
Isoxicam- NSAIDs - Investigational drugs
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Use of aspirin with NSAIDs is not recommended because of aspirin indiced reactions of
blood vessels and lack of thrapeutic advantage with concomittant use
When used with warfarin, isoxicam potentiates warfarins anticoagulant effect
Monitor the prothrombin time in patients on both agents more frequently and adjust sodium
warfarin dosage, if needed
No interaction occurs between cimetidine and isoxicam
Indication:
Rheumatoid Arthriritis (RA)
Dengenerarive joint diseas (DJD)
Summary-
Isoxicam is a novel NSAID of the oxicam class. It appears to be as effective as or superior to aspirin and non aspirin agents for the treatment of common rheumatic disorders.
The ability to administer isoxicam once a day is an important advantage .
Parke-Davis ( Warner Lambert) submitted an NDA for isoxicam in August 1983, to be marketed under the name MAXICAM. The drug was withdrawn from Europeon market in October 1985 following reports of adverse skin reactions during which time the NDA was pending in the US.
In 1987 , Warner Lambert asked the FDA to reactivate the NDA since the skin reactions were apparently due to manufacturing by product.
Adverse Reaction:
Isoxicam has so far been well tolerated and has caused few probems other
gastrointestinal effects.
Other less commonly reported adverse reactions include,
Headache, dizziness, and tinnitus
A higher than anticipated rate of skin reactions has occured in foreign countries
where isoxicam is available
Pharmacology/ Pharmacokinetics:
Pharmacology-
Isoxicam, like piroxicam (Feldane) is a member of oxicam class of drugs.
It is about on-tenth as potent ( on a weight basis) as piroxicam and has a long duration of action which permits once-daily dosing.
Clinical studies show it to be as effective as o as superior to other NSAIDs , isoxicam is
well tolerated , GI disturbances is the most comon side effect.
Pharmacokinetics-
Isoxicam is well absorbed orally and generally reaches and generally reaches peak plasma
concentration 4 to 8 hours after administration. Both the rate and extent of absorption increase when given with meals.
Isoxicam is 95% protein bound. It is extensively metabolised with only 1% to2% of the dose
appearing in the urine as unchanged drug.
Because of its long half-life, steady state levels occur after 1 to 2 weeks of daily administration